FDA accepted for review an sNDA for MIUDELLA copper IUD for a 6-year duration, with a PDUFA date in Q2 2027.
|Podcasts|February 28, 2022
Caring for women who are or have been incarcerated: contraception, sexual health, and trauma-informed care
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Advertisement
Advertisement
Related to this article
A recap of the top videos and podcasts from Contemporary OB/GYN in September 2026, featuring expert interviews on salpingectomy, testosterone evidence, and more.
A recap of the top headlines from Contemporary OB/GYN in September 2026, spanning ACOG's respiratory vaccine guidance to the launch of the Missed & Dismissed podcast.
A recap of Contemporary OB/GYN's top FDA and regulatory news from September 2026.
Anita Nelson, MD, discusses the FDA's approval extending etonogestrel implant use to 5 years and the new REMS certification clinicians must complete by February 23, 2027.
A new book from Sameena Rahman, MD, reclaims "brown girls' disease" as a lens for examining how dismissal—of conditions, anatomy, and patients—undermines sexual medicine care for all women.
Wen Shen, MD, describes perimenopause as an opportunity for clinicians to revisit pregnancy-related risk factors and address cardiovascular health proactively.
A new study finds that low birth volume and unprofitability were strongly associated with both obstetric unit and full hospital closures between 2010 and 2023.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
IMS: Fezolinetant's improvements in sleep quality, hot flashes as early as week 4
2
Top headlines in women's health from September 2026
3
Wen Shen, MD, on recognizing perimenopause as a window for healthy aging
4
FDA grants priority review to elinzanetant for VMS in women receiving endocrine therapy for breast cancer
5